Cipher Pharmaceuticals Inc
TSX:CPH

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
TSX:CPH
Watchlist
Price: 14.9 CAD -1.06% Market Closed
Market Cap: 378m CAD

Cipher Pharmaceuticals Inc
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cipher Pharmaceuticals Inc
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Cipher Pharmaceuticals Inc
TSX:CPH
EPS (Diluted)
$0
CAGR 3-Years
21%
CAGR 5-Years
18%
CAGR 10-Years
19%
Bausch Health Companies Inc
TSX:BHC
EPS (Diluted)
$0
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
-5%
Canopy Growth Corp
TSX:WEED
EPS (Diluted)
-CA$1
CAGR 3-Years
40%
CAGR 5-Years
19%
CAGR 10-Years
N/A
Sundial Growers Inc
NASDAQ:SNDL
EPS (Diluted)
CA$0
CAGR 3-Years
32%
CAGR 5-Years
53%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
EPS (Diluted)
$0
CAGR 3-Years
N/A
CAGR 5-Years
-20%
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
EPS (Diluted)
CA$0
CAGR 3-Years
41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cipher Pharmaceuticals Inc
Glance View

Market Cap
378m CAD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPH Intrinsic Value
17.8 CAD
Undervaluation 16%
Intrinsic Value
Price

See Also

What is Cipher Pharmaceuticals Inc's EPS (Diluted)?
EPS (Diluted)
0.7 USD

Based on the financial report for Sep 30, 2025, Cipher Pharmaceuticals Inc's EPS (Diluted) amounts to 0.7 USD.

What is Cipher Pharmaceuticals Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
19%

Over the last year, the EPS (Diluted) growth was 3%. The average annual EPS (Diluted) growth rates for Cipher Pharmaceuticals Inc have been 21% over the past three years , 18% over the past five years , and 19% over the past ten years .

Back to Top